Global Cervical Dysplasia Diagnostic Market Is Expected To Reach US$ 791.3 Mn By 2025

According to the latest market report published by Credence Research, Inc. “Cervical Dysplasia Diagnostic Market – Growth, Future Prospects, and Competitive Analysis, 2017 – 2025,” the global cervical dysplasia diagnostic market was valued at US$ 437.3 Mn in 2016, and is expected to reach US$ 791.3 Mn by 2025, expanding at a CAGR of 6.5% from 2017 to 2025

Browse the full report Cervical Dysplasia Diagnostic Market – Growth, Future Prospects and Competitive Analysis, 2017 – 2025 report at

Market Insights

Cervical dysplasia, also known as cervical intraepithelial neoplasia (CIN), causes abnormal cell growth that occurs on the epithelial lining of the cervix. It is the precancerous condition of the cervix which in an average of 10-15 years would progress to cervical cancer. It is common health problem observed in among women. WHO and national governments are taking initiatives for providing screening program and effective education to promote preventive practices among women. Annually around 250,000 to 1 million women in the U.S. are diagnosed with cervical dysplasia. The peak incidence in women ranges from age 25 -35 and if not diagnosed or treated at the earliest may progress in 30-40% cases into invasive cancer. Cervical cancer is a global burden, especially in developing countries where it is the most common cause of preventable cancer-related mortality. Thus rising incidence of cervical dysplasia and advancement in diagnostic technology and treatment option are the key factors contributing the growth of cervical dysplasia diagnostic market.

The global cervical dysplasia diagnostic market is segmented by diagnosis type into diagnostic test and diagnostic devices. Diagnostic test types is further segmented into HPV test, pap smear test and biopsy.

As of the current market scenario, North America dominates the global cervical dysplasia diagnostic market followed by the Europe. Rise in incidence of cervical dysplasia, advancement in diagnostic technology, awareness about cervical cancer and available novel treatment option are some of the major factors driving the growth of cervical dysplasia diagnostic market in North America and Europe. Asia Pacific is the fastest growing regional market for cervical dysplasia with highest CAGR in the forecast period.

Market Competition Assessment:

Key players in the global cervical dysplasia diagnostic market are Abbott Laboratories, Becton, Dickinson and Company, F. Hoffmann La-Roche Ltd., GlaxoSmithKline Plc, Helix BioPharma Corp., Hologic, Inc., Inovio Biomedical Corporation, Micromedic Technologies Ltd., OncoHealth Corporation, PDS Biotechnology Corporation, Photocure ASA, Quest Diagnostics, Inc., QIAGEN N.V. and others.

Key Market Movements:

  • Increase in incidence and mortality of cervical cancer is leading to global burden especially in developing countries. In developed countries government is taking initiatives for screening programs with goal of early diagnosis and treatment of cervical dysplasia which play pivotal role in growth of cervical dysplasia diagnostic market.
  • Advancement in diagnostic technology and novel drug treatment option available in market would further propel the growth of cervical dysplasia diagnostic market.